Evidence map›Paper›PMID 35416831›Full record

ArticleEinstein (Sao Paulo, Brazil)2022

Functionality assessment in patients with rheumatic diseases undergoing treatment in the Public Health System.

Elisa Neide Barbosa de Souza, Michael Ruberson Ribeiro da Silva, Jéssica Barreto Ribeiro Dos Santos, Edna Afonso Reis, Juliana Alvares-Teodoro, Francisco de Assis Acurcio, Alessandra Maciel Almeida

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Einstein (Sao Paulo, Brazil), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 93% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Elisa Neide Barbosa de SouzaFaculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.ORCID http://orcid.org/0000-0003-3083-5431
Michael Ruberson Ribeiro da SilvaUniversidade Federal do Espirito Santo, Alegre, ES, Brazil.ORCID http://orcid.org/0000-0003-2550-7249
Jéssica Barreto Ribeiro Dos SantosUniversidade Federal do Espirito Santo, Alegre, ES, Brazil.ORCID http://orcid.org/0000-0002-5528-0658
Edna Afonso ReisFaculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.ORCID http://orcid.org/0000-0003-1465-9167
Juliana Alvares-TeodoroFaculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.ORCID http://orcid.org/0000-0002-0210-0721
Francisco de Assis AcurcioFaculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.ORCID http://orcid.org/0000-0002-5880-5261
Alessandra Maciel AlmeidaFaculdade de Ciências Médicas de Minas Gerais, Belo Horizonte, MG, Brazil.ORCID http://orcid.org/0000-0003-0138-9401
Universidade Federal de Minas Gerais · BRUniversidade Federal do Espírito Santo · BRFaculdade de Ciências Médicas de Minas Gerais · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate the therapeutic response (functionality) and its associated factors in patients on biological drugs on the Public Health System for treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.

methodsAn open prospective cohort was carried out from 2011 to 2019, in Belo Horizonte (MG). Functionality was assessed using the Health Assessment Questionnaire Disability-Index at baseline, and after 6 and 12 months of follow-up. Factors associated with poor functionality were identified through logistic regression.

resultsThe median Health Assessment Questionnaire Disability-Index at baseline was 1.5 (interquartile range of 0.8-1.9), with poor functionality observed in patients with rheumatoid arthritis. Improved functionality was seen at 6 months of treatment for the three diseases. The predictors of poor functionality at 6 months for psoriatic arthritis and ankylosing spondylitis were female sex, low education levels, and high disease activity; and for rheumatoid arthritis and psoriatic arthritis were female sex, advanced age, and high disease activity. In 12 months, the three diseases had predictors of worse functionality: female sex, low education, and high disease activity.

conclusionThere was a significant improvement in functionality during the follow-up, with better response at 6 months of treatment. Poor functionality was observed in older, female patients, with low education and high disease activity.

Indexed as

Antirheumatic AgentsArthritis, PsoriaticArthritis, RheumatoidRheumatic DiseasesSpondylitis, AnkylosingAgedFemaleHumansMaleProspective StudiesPublic HealthAntirheumatic Agents

Identifiers

PMID35416831
PMCPMC9648950
OpenAlexW4225539128

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.